The words no DAC are essential to reading a CJC-1295 listing. They indicate that the material should not be treated as the same structural entity as the long-acting, albumin-binding molecule in the best-known CJC-1295 studies. Dropping those two words can turn a correct study result into an incorrect product claim.
What does DAC mean here?
DAC refers to a drug affinity complex associated with a reactive modification that enables attachment to albumin, a blood protein. In the 2005 development paper, researchers studied modified growth-hormone-releasing-factor peptides capable of forming albumin conjugates. CJC-1295 was selected as a long-lasting analogue after laboratory and rat experiments.
In plain English, the peptide was engineered to attach to a much larger circulating partner. That structural feature is part of the explanation for prolonged exposure. It is not a decorative suffix or a statement about purity. A material described as no DAC needs its own identity record and cannot inherit the conjugated molecule's persistence by sharing part of its name.
What the catalogue designation does and does not resolve
This catalogue uses CJC-1295 (no DAC). The phrase modified GRF(1–29) also appears in discussions of related non-DAC material. Treat that as a search term to investigate, not automatic confirmation that any vial bearing either name has the same sequence and terminal chemistry. Request the exact structure, expected molecular mass and analytical identity evidence.
A 2010 analytical investigation illustrates the naming problem. Researchers identified a 29-amino-acid amidated peptide in an unknown preparation and described its sequence as consistent with material marketed under the CJC-1295 name. This is identity research on a particular sample, not a demonstration that all products using the name are interchangeable.
| Record | What it concerns | What cannot be assumed |
|---|---|---|
| 2005 development work | Albumin-conjugating GHRH-related analogues | The same persistence for no-DAC material |
| 2006 human trial | Long-acting CJC-1295 and hormone measurements | Clinical outcomes for a different structure |
| 2010 analytical investigation | A particular 29-residue amidated sample | Identity of every subsequently marketed batch |
What the classic human study actually measured
The 2006 trial report studied the long-acting analogue in healthy adults. It measured drug exposure and growth-hormone and IGF-I responses, reporting a multi-day half-life. Those results describe that investigational molecule and study protocol. They do not establish a numerical half-life for this no-DAC catalogue format.
GH is growth hormone; IGF-I is an associated growth-factor signal. Measuring either is a pharmacodynamic observation: evidence that a biological system responded. It is not a direct measurement of strength, recovery, sleep quality or long-term health. Claims about those outcomes would require studies designed to assess them.
Pulse patterns need their own measurement
A separate 2006 study of the long-acting molecule reported preserved GH pulsatility with increased trough and mean secretion. This matters because long-acting does not automatically mean pulses disappear. Conversely, no DAC does not by itself prove a normal or preferable hormone pattern.
A pulse is a change over time. One blood measurement cannot describe an entire pattern. A credible pulse claim needs repeated sampling, an appropriate analysis and the exact study material. Illustrations that show attractive pulse shapes without measured data should be labelled conceptual rather than presented as results.
A useful identity checklist
| Field | Question |
|---|---|
| Sequence and termini | Do the amino-acid sequence and terminal modifications match? |
| Albumin-binding modification | Is it present, absent or undocumented? |
| Analytical result | Does the measured identity support the declared form? |
| Study endpoint | Was the claim about exposure, hormones or a clinical outcome? |
Frequently asked questions
Can I use the published multi-day half-life for no-DAC material?
No. That number belongs to the long-acting molecule in its study. Removing a defining structural feature prevents a direct transfer of the estimate.
Is no DAC a guarantee of safety?
No. A structural distinction is not a comparative safety trial. Neither a short nor long exposure profile establishes safety by itself.
Where does the Ipamorelin combination fit?
It introduces a second component and another evidence question. Read the CJC no DAC plus Ipamorelin analysis. The 10 mg single-compound listing here remains laboratory material, not a personal-use protocol.
